HOUSTON, TEXAS (July 10, 2018) – Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, announced today it has hired three additional team members to support the advancement of its intra-aortic heart pump, AortixTM, for use in NYHA Class III-IV heart failure patients. Patricia DaSilva, Margo Fendrich, and Aaron Stone will focus on product development and operations, further strengthening the company’s team as they push toward clinical studies.
“We’ve spent the past 12 months finetuning the design of Aortix and closing a $16 million Series C. Now, we are in a rapid growth phase to support continued development of the Aortix system,” said Ben Hertzog, Chief Executive Officer of Procyrion. “We are excited to have Patricia, Margo and Aaron join the Procyrion team. They bring a mix of technical and operation experience, and we look forward to their immediate contributions to Procyrion’s success.”
Patricia DaSilva, Product Development Engineer
Earning a Bioengineering degree from Rice University, DaSilva focused on bioinstrumentation to address complex problems of medical care. DaSilva brings experience designing instruments and devices, utilizing a variety of sources to gain insights in order to develop new procedures, and carried out research to acquire knowledge needed to solve new problems. Prior to Procyrion, DaSilva was a Biomedical R&D Engineer for Paratus Diagnostics.
Margo Fendrich, Business Operations Associate
Overseeing and completing complex projects utilizing scrum framework, Fendrich’s career has focused on analysis, problem identification and resolution, operation of complex software systems, distribution logistics, cognitive neuroscience, medical humanities, and academic research. Prior to Procyrion, Fendrich was Product Manager for health tech startup, BrainCheck.
Aaron Stone, Product Development Engineer
Earning his master’s in mechanical engineering from Texas A&M, Stone has an abundance of experience in the development and design of custom testing systems for biomechanical experimentation and evaluation of hardware.
Procyrion’s novel technology, Aortix, which is thinner than a #2 pencil, is the first catheter-based heart pump designed specifically to address cardiorenal syndrome in chronic heart failure patients who are failing medical therapy, but not sick enough for risky surgical interventions like heart transplants or LVADs. The unique placement of the small but powerful micropump in the descending thoracic aorta is intended to simultaneously unload the heart and support the kidneys by accelerating native blood flow in the aorta.
Procyrion Inc., headquartered in Houston, Texas, is developing catheter-based circulatory support technologies to address the significant unmet clinical need in the large chronic heart failure population. Aortix is not approved for sale in any geography.